INTRODUCTION {#s1}
============

Adrenocortical carcinoma (ACC) is an extremely rare malignancy, with an incidence of 0.7--2.0/million/year ([@MCS003764MCCC24]). In 40%--60% of patients, ACC is diagnosed after the patient presents with clinical features of steroid excess (usually hypercortisolemia or Cushing\'s syndrome). Thirty percent of patients may present with an abdominal mass, and some 20%--30% of ACC may be incidental findings on unrelated imaging ([@MCS003764MCCC42]). Surgery is the primary treatment modality, often followed by adjuvant radiotherapy to the adrenal bed, mitotane or cytotoxic drugs, or a combination thereof ([@MCS003764MCCC24]). Pathology scoring relies heavily on the Weiss system, and the proliferation marker Ki67, where \<10% or \>10% Ki67 positivity, corresponds to low- and high-grade tumors respectively ([@MCS003764MCCC42]). The Weiss system, assessed on a scale of 1--9, provides guidelines for differentiating adrenocortical adenoma from ACC. Studies have demonstrated an association between the Weiss score and survival ([@MCS003764MCCC67]). For instance, patients who score ≤3 have better prognoses ([@MCS003764MCCC46]; [@MCS003764MCCC42]). Stage I ACC are ≤5 cm, are strictly localized to the adrenal, and have a 5-yr survival of 81% ([@MCS003764MCCC24]); however, just 3%--6% of patients present at this stage ([@MCS003764MCCC44]). Stage II ACC are localized but \>5 cm. In Stage III, tumor invades surrounding lymph nodes or the renal vein, whereas Stage IV represents metastatic disease ([@MCS003764MCCC24]). Five-year survival declines dramatically with increasing stage---being 61% in Stage II, 50% in Stage III, and 13% in Stage IV ([@MCS003764MCCC24]).

To date, mitotane is the only drug approved for adjuvant therapy of ACC, although there are no guidelines and poor consensus for its use ([@MCS003764MCCC5]). It is a cytostatic and antineoplastic agent that works at the mitochondrial level to suppress steroidogenesis, but it is difficult to manage because of its long half-life, dose-limiting toxicity, and severe side effects ([@MCS003764MCCC8]). Its adrenolytic activity means all patients require concomitant glucocorticoids ([@MCS003764MCCC8]). Mitotane is recommended in patients with Ki67 of \>10% and tumor size \>8 cm, and those with potential residual disease following resection ([@MCS003764MCCC8]). However, there is a low complete response rate (\<10%) to treatment ([@MCS003764MCCC58]). Patients with metastatic disease receive conventional chemotherapy, either a combination of streptozocin plus mitotane, or etoposide, doxorubicin, and cisplatin plus mitotane. Response rates are poor; 23% for the latter treatment versus 9% for the former, with little long-term benefit and significant side effects ([@MCS003764MCCC23]).

The lack of adjuvant therapies and poor response rates to targeted therapies such as linsitinib ([@MCS003764MCCC25]), sunitinib ([@MCS003764MCCC38]), and bevacizumab plus capecitabine ([@MCS003764MCCC70]) are exacerbated by the dearth of preclinical models, as well as limited molecular stratification of these malignancies ([@MCS003764MCCC32]). Genomic stratification of common cancers has helped inform diagnoses (predominantly from a risk stratification perspective) and inform novel treatment options that have led to a marked improvement in prognoses or the quality and duration of life in some patients. In landmark studies, next-generation sequencing (NGS) identified therapeutically actionable mutations in 76% of 2221 tumor samples of various types studied and has also facilitated successful repurposing of existing therapeutics ([@MCS003764MCCC7]; [@MCS003764MCCC27]). Over time, however, many of these targeted therapies have become ineffective because of ongoing tumor evolution leading to the eventual acquisition of tumor resistance. For instance, 20% of melanoma patients sustained a response to MAPK-targeting treatments, whereas another subset of patients had life extended by 10 yr with the checkpoint inhibitor ipilimumab ([@MCS003764MCCC43]), but after 12 mo resistance to the therapies emerged in most patients. Targetable genetic changes are highly likely to be detected in other less common malignancies also, but like their common-cancer counterparts, the buildup of resistance needs to be countered.

This may potentially be mediated through liquid biopsy for circulating tumor DNA (ctDNA), which is also emerging as a powerful tool for the real-time monitoring of tumor burden or for early detection of cancer initiation or recurrence ([@MCS003764MCCC18]; [@MCS003764MCCC68] [@MCS003764MCCC43]; [@MCS003764MCCC49]). Small surgical core biopsies are spatiotemporally constrained, informing a limited choice of targeted therapeutic options and allowing missed tumoral subclones to develop, leading to drug resistance. Liquid biopsy potentially negates this, by providing a global picture of all mutations in real time and informing broader treatment plans ([@MCS003764MCCC43]). Recent studies have applied NGS and liquid biopsy to improve the molecular stratification of ACC, as well as monitor tumor burden and its response to treatment ([@MCS003764MCCC17]; [@MCS003764MCCC3]; [@MCS003764MCCC28]).

At the germline level, mutations in *TP53* are found in 7.5% of ACC cases generally, but much more frequently (50%--97%) in childhood ACC ([@MCS003764MCCC57]). Further germline mutations have been identified in several genes on Chromosome 11p15 ([@MCS003764MCCC21]) and *BRCA2* ([@MCS003764MCCC20]). Somatically, dysregulation of protein kinase A and mutations in *ADIPOR1*, *ADIPOR2*, *APC*, *ARMC5*, *SDHA*, *SDHC*, *SF1*, and *IGF2*, among others, have also been implicated as mediators of ACC tumorigenesis, along with mutations in *RB1* and *APC* ([@MCS003764MCCC6]; [@MCS003764MCCC22]). Recent expression studies have identified sonic hedgehog and somatostatin receptor pathways activated in ACC, along with markedly increased expression in cytosolic protein Stathmin1, SLC12A7 and phospho-mTOR, EGFR, and WNT/β-catenin signaling pathways ([@MCS003764MCCC31]; [@MCS003764MCCC4]; [@MCS003764MCCC10],[@MCS003764MCCC11]; [@MCS003764MCCC33]). At the miRNA level, miR-483-3p and miR-139-5p promote ACC aggressiveness ([@MCS003764MCCC1]). These studies have led to the emergence of potential new drug targets or targeted therapies, such as *VAV2*, Nutlin-3a, and the GRP78/BiP inhibitor HA15 ([@MCS003764MCCC60]; [@MCS003764MCCC36]; [@MCS003764MCCC61]).

We hypothesized that a genomics-based strategy could identify optimal treatment options when presented with metastatic ACC. We aimed to perform this using whole-genome or targeted sequencing on primary and metastatic tissue, as well as monitor for early relapse by serial liquid biopsy for ctDNA analysis.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A 37-yr-old female Caucasian patient was diagnosed with stage II, high-grade ACC in April 2014, after presenting with abdominal pain and symptoms of cortisol and androgen excess. Abdominal imaging revealed a large heterogeneous, right-sided adrenal mass, measuring 11 × 14 × 17 cm ([Fig. 1](#MCS003764MCCF1){ref-type="fig"}A--D). Hormone measurements confirmed Cushing\'s syndrome and hyperandrogenism, consistent with a glucocorticoid and androgen-producing tumor ([Table 1](#MCS003764MCCTB1){ref-type="table"}). The patient was a fragile X carrier and has a son with fragile X syndrome. There was no personal or family history of malignancy.

![A case with metastatic ACC. Abdominal (*A*) and whole-body computed tomography (CT) (*C*) and positron emission tomography (PET) (*B*) scanning in March 2014, of a large, right-sided adrenal mass (red arrow and red asterisks), which underwent immediate adrenalectomy with nephrectomy (*D*, white asterisk). Grading of the tumor was assessed by Ki67 (*E*) and Weiss scoring. The Ki67 image is presented alongside H&E (*F*) and programmed cell death ligand-1 (PD-L1) (*G*) staining. An enlarged inset image is provided for PD-L1, with the dashed line separating positively staining cells from negative cells. Follow-up (May 2015) PET (*H*) and CT (*I*) scan imaging demonstrating bilateral lung nodules (red circles).](MCS003764Mcc_F1){#MCS003764MCCF1}

###### 

ACC patient biochemistry

  Hormone                                            March 2014 preoperative   April 2014 postoperative   April 2015   February 2016   June 2017   November 2017   May 2018
  -------------------------------------------------- ------------------------- -------------------------- ------------ --------------- ----------- --------------- ----------
  Cortisol (150--520 nmol/L)                         **748**                   33                                      464             445         309             397
  ACTH (0--12 pmol/L)                                \<2.2                                                             **24.9**        **14.0**    **13.7**        **17.5**
  Midnight salivary cortisol (0--10 nmol/L)          **19**                                                                                                        
  24 UFC (0--250 nmol/d)                             **414**                                                                                                       
  1 mg overnight DST                                 **680**                                                                                                       
  Low-dose DST                                       **505**                                                                                                       
  DHEAS (premenopausal 2.2--9.1 µmol/L)              6.9                       \<0.9                      \<0.9        \<0.9           0.4         \<0.4           \<0.4
  Androstenedione (premenopausal 2.5--10 nmol/L)     **30**                    0.3                        1.6          1.6             1.6         2.1             2.6
  Testosterone (0--1.8 nmol/L)                       **4.9**                   \<0.3                      \<0.3        \<0.3           \<0.3       \<0.3           \<0.3
  Free testosterone (0--24 pmol/L)                   **71**                                                                            \<6                         
  SHBG (20--110 nmol/L)                              61                                                                                                            
  17 OH Progesterone (1.2--17 nmol/L luteal phase)   **55.9**                                                                                                      
  Plasma catecholamines                              Normal                                                                                                        
  Urine catecholamines                               Normal                                                                                                        
  Aldosterone/renin ratio                            0.5                                                                                                           

Bold type indicates numbers that exceed the normal range provided in the first column. (ACTH) Adrenocorticotropic hormone, (DHEAS) dehydroepiandrosterone, (DST) dexamethasone suppression test, (SHBG) sex hormone-binding globulin, (UFC) urine-free cortisol.

A right adrenalectomy/nephrectomy was performed in April 2014, with no lymphadenopathy or distant metastases identified. Histopathology revealed high-grade ACC with lymphovascular invasion but clear margins. Ki67 index was elevated at 60%--75% and PD-L1 staining of 1% ([Fig. 1](#MCS003764MCCF1){ref-type="fig"}E--G). PD-L1-positive cells exhibited diffuse cytoplasmic staining that was sharper at the membrane, and were larger than surrounding, PD-L1-negative cells ([Fig. 1](#MCS003764MCCF1){ref-type="fig"}G, inset). The tumor had a Weiss score of 5. Following resection, blood and urine steroid profiling revealed reductions in the previously elevated metabolites and precursors ([Tables 1](#MCS003764MCCTB1){ref-type="table"} and [2](#MCS003764MCCTB2){ref-type="table"}), except urine TH cortisone/cortisol postoperatively, because of the patient\'s Hysone (hydrocortisone) treatment. The patient completed adjuvant fractionated adrenal bed radiotherapy and commenced mitotane in June 2014. Therapy was complicated by reversible hepatotoxicity and central hypothyroidism.

###### 

ACC patient 24-h urine steroid profile

  Hormone                                 March 2014 preoperative   April 2014 postoperative   June 2015   February 2016   October 2016   June 2017   November 2017
  --------------------------------------- ------------------------- -------------------------- ----------- --------------- -------------- ----------- ---------------
  Androsterone (1.5--12 µmol/24 h)        **13.6**                  0.3                        0.3         0.8             0.2            0.1         0.1
  Etiocholanolone (1.5--12 µmol/24 h)     37.2                      0.7                        0.3         1.1             2.0            0.6         0.8
  5b 17A OHPNL (\<1 µmol/24 h)            **14.8**                  \<0.1                      0.2         **2.1**         0.6            0.1         0.1
  Pregnanetriol (0.5--3.5 µmol/24 h)      **9.1**                   0.4                        0.1         2.2             **6.2**        0.5         0.7
  TH-11 deoxycortisol (\<0.5 µmol/24 h)   **5.5**                   \<0.1                      0.2         0.3             0.3            0.1         0.3
  TH cortisone (2.5--12 µmol/24 h)        9.6                       **22.4**                   3.1         8.5             8.3            5.7         6.2
  TH cortisol (0.7--6.0 µmol/24 h)        **11.8**                  **32.3**                   5.8         **7.6**         3.6            4.6         3.9

The bold type indicates numbers that exceed the normal range provided in the first column. (OHPNL) Hydroxypregnenolone, (TH) tetrahydro.

Despite maintaining low circulating and urine adrenal steroids in the year following surgery ([Tables 1](#MCS003764MCCTB1){ref-type="table"} and [2](#MCS003764MCCTB2){ref-type="table"}), single bilateral lung ACC metastases (10 mm, right middle lobe; 13 mm, left lower lobe) were identified on routine surveillance imaging in May 2015 ([Fig. 1](#MCS003764MCCF1){ref-type="fig"}H,I), with subsequent wedge resections in June (right lung metastasis \[RLM\]) and July (left lung metastasis \[LLM\]). Following the development of metastatic disease, mitotane therapy was ceased. The patient has received no additional radiotherapy or systemic therapy. Now 3.5 yr later, urine steroid profiling and serial imaging (PET or CT) performed every 3--6 mo, have not suggested further recurrence.

Genomic Analyses and Fluorescence In Situ Hybridization (FISH) {#s2b}
--------------------------------------------------------------

Targeted sequencing of the primary tumor to a mean depth of 512× revealed a tumor of high cellularity/purity (85%), with a large proportion of haploid cells suggestive of a mass loss-of-heterozygosity (LOH)/haploidization event. This was confirmed by FISH, which identified 47% of cells as haploid ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)). Only chromosomes 5, 7, 9, 19, and 21 remained diploid, and the tumor exhibited a tumor mutation burden (TMB) of 15.8 mutations/Mb.

As metastatic tissue had been derived from fresh-frozen sources, we could conduct a more extensive, WGS characterization compared to the primary tumor. As per the primary tumor, hyperhaploidy was detected in both metastases: in 77% of cells in the LLM ([Fig. 2](#MCS003764MCCF2){ref-type="fig"}A,C; 71% pure) and 88% of cells in the RLM ([Fig. 2](#MCS003764MCCF2){ref-type="fig"}B,D; 82% pure). Both metastatic lesions were likely derived from the same clone carrying the hyperhaploidization event seen in the primary tumor. The most apparent difference between metastases was in Chromosome 18, which was diploid in the LLM ([Fig. 2](#MCS003764MCCF2){ref-type="fig"}A), and the RLM had a subclonal deletion ([Fig. 2](#MCS003764MCCF2){ref-type="fig"}B). There were very few structural variants observed in either metastasis, but high levels of indels and single-nucleotide variants (SNVs), with a preponderance of C\>T SNVs occurring in both ([Fig. 2](#MCS003764MCCF2){ref-type="fig"}A,B).

![Both metastases are hyperhaploid. Circos plots generated following WGS of the patient\'s left lung metastasis (*A*) and right lung metastasis (*B*). From the outside of the Circos plots toward the center, chromosomes are first numbered from 1 to 22 and X. SNVs, C\>A (blue), C\>G (black), C\>T (red), T\>A (grey), T\>C (green), and T\>G (pink), are then represented as dots and ordered by their genomic location and variant allele frequency (VAF). The next ring shows the locations of small indels (orange). Next, purity-adjusted chromosomal copy number levels are represented in green (amplifications) and red (deletions) (scale 0--8). The innermost ring shows the copy number of the minor allele, highlighting that most chromosomes exhibit loss of heterozygosity (orange). The center of the plots represent structural variants including deletions (red), duplications (green), inversions (black), and translocations (blue). The hyperhaploid tumors were confirmed with fluorescence in situ hybridization probing Chromosomes 9 (red) and 22 (green). (*C*,*D*) White circles represent example haploid cells; cell nuclei are highlighted in blue.](MCS003764Mcc_F2){#MCS003764MCCF2}

The TMBs of the LLM and RLM were similar to the primary, at 15.1 and 17.5 mutations/Mb respectively, which are considered to be high ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}A). By comparing the mutations observed in both metastases, we identified a total of 50,289 somatic variants, of which 24,735 were shared, and 8237 and 17,317 were private to the LLM and RLM respectively ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}B). Mutational signature analysis revealed a strong signal for defective DNA mismatch repair (MMR), along with strong signals for deamination of 5-methylcytosine and polymerase η; all attributable to C\>T mutations ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}B). Filtering and prioritization of the somatic variant data, revealed a 24-bp deletion, overlapping a splice acceptor in the MMR gene *MSH2*, as well as six functionally deleterious mutations, in *IGF2R*, *PTPRD*, *PTEN*, *MEN1*, *RB1*, and *TP53* ([Table 3](#MCS003764MCCTB3){ref-type="table"}). All were validated by deep targeted sequencing (data not shown). The *MSH2* deletion, and *RB1* and *TP53* mutations were also detected in the primary tumor. The *PTEN* nonsense mutation detected in the metastases was not detected in the primary, whereas *IGF2R*, *PTRPD*, and *MEN1*, were not targeted for sequencing in the primary. A functionally deleterious missense variant, c.793C\>T, p.Arg265Cys was detected in MMR gene *MLH1* in the primary, but not in the metastases.

![Both metastases have microsatellite instability. Plot of tumor mutation burden (TMB) mutation counts/Mb for primary tumor and each metastasis (*A*). Phylogenetic analysis of variants shared between, or private to either metastasis, plus somatic mutation signature analysis indicating the combined and private drivers of tumor pathology (*B*). Microsatellite instability (MSI) analysis was conducted using Mantis, with both metastases (blue) plotted against the recommended threshold for MSI-high tumors (red dashed line) (*C*). This was checked by immunohistochemistry for PD-L1 (*D*,*F*). Images are presented alongside H&E stains (*E*,*G*) and in magnified *insets*.](MCS003764Mcc_F3){#MCS003764MCCF3}

###### 

Filtered variants of interest

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene      Chromosome     HGVS DNA reference   HGVS protein reference   Variant type      Predicted effect         dbSNP/dbVAR ID   LOH   Tumor tissue detection (VAF)
  --------- -------------- -------------------- ------------------------ ----------------- ------------------------ ---------------- ----- ------------------------------
  *IGF2R*   6:160515930\   c.3949dup            p.Asp1317GlyfsTer5       Frameshift        LOF, dominant negative                    Yes   Primary (NA)\
            GRCh37                                                                                                                         Left lung metastasis (0.00)\
                                                                                                                                           Right lung metastasis (0.70)

  *PTPRD*   9:8341226\     c.3772G\>A           p.Ala1258Thr             Missense          Probably damaging                         No    Primary (NA)\
            GRCh37                                                                                                                         Left lung metastasis (0.40)\
                                                                                                                                           Right lung metastasis (0.38)

  *PTEN*    10:89717672\   NM_000314.6\         NP_000305.3\             Stop gain         LOF                      rs121909219      Yes   Primary (0.00)\
            GRCh37         c.697C\>T            p.Arg233Ter                                                                                Left lung metastasis (0.48)\
                                                                                                                                           Right lung metastasis (0.68)

  *MEN1*    11:64572093\   NM_130799.2\         NP_000235.2\             Frameshift        LOF                      rs794728642      Yes   Primary (NA)\
            GRCh37         c.1561delC           p.Arg521GlyfsTer43                                                                         Left lung metastasis (0.00)\
                                                                                                                                           Right lung metastasis (0.26)

  *RB1*     13:48941648\   NM_000321.2\         NP_000312.2\             Stop gain         LOF, LOH                 rs121913300      Yes   Primary (0.91)\
            GRCh37         c.958C\>T            p.Arg320Ter                                                                                Left lung metastasis (0.63)\
                                                                                                                                           Right lung metastasis (0.70)

  *TP53*    17:7577548\    NM_000546.5\         NP_000537.3\             Missense          LOF, LOH                 rs28934575       Yes   Primary (0.90)\
            GRCh37         c.733G\>A            p.Gly245Ser                                                                                Left lung metastasis (0.58)\
                                                                                                                                           Right lung metastasis (0.74)

  *MSH2*    2:47672676\    c.1277-9_1292del                              Splice critical   LOF, LOH                                  Yes   Primary (0.95)\
            GRCh37                                                                                                                         Left lung metastasis (0.46)\
                                                                                                                                           Right lung metastasis (0.63)

  *MLH1*    3:37058999\    NM_000249.3\         NP_000240.1\             Missense          LOF                      rs63751194       Yes   Primary (0.03)\
            GRCh37         c.793C\>T            p.Arg265Cys                                                                                Left lung metastasis (0.00)\
                                                                                                                                           Right lung metastasis (0.00)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

(LOF) Loss of function, (LOH) loss of heterozygosity, (NA) not applicable, (VAF) variant allele frequency.

Microsatellite Instability (MSI) Analysis and Immunological Assessment of Tumors {#s2c}
--------------------------------------------------------------------------------

Given the deletion detected in *MSH2*, we assessed both metastatic tumors for MSI, and confirmed its presence in both cases ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}C). Immunohistochemical staining of metastatic tumors revealed the absence of MSH2 but the presence of MLH1, PMS2, and MSH6 (data not shown). Interestingly, subsequent immunohistochemical staining for PD-L1 revealed marked increases in staining positivity for the LLM (70%) and RLM (20%) compared to the primary (1%) ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}D--G; shown with corresponding hematoxylin and eosin \[H&E\] stains). As per the primary tumor, PD-L1-positive cells appeared larger than negative cells ([Fig. 3](#MCS003764MCCF3){ref-type="fig"}D,F, insets). We next examined the LLM for the degree of T-cell infiltration by immunohistochemistry and T-cell receptor sequencing. These analyses revealed little to no immune infiltrate within the tumor ([Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)).

Cellular Staining of Mitochondria {#s2d}
---------------------------------

We hypothesized that the large swollen cells reported in [Figures 1](#MCS003764MCCF1){ref-type="fig"} and [3](#MCS003764MCCF3){ref-type="fig"} were oncocytes; a common ACC cell type, characterized by an accumulation of mitochondria, and often exhibiting mass haploidization ([@MCS003764MCCC16]). Careful assessment of our patient\'s primary and metastatic tumor tissue revealed this to be the case, with oncocytes packed with SDHB-positive mitochondria ([Fig. 4](#MCS003764MCCF4){ref-type="fig"}). Only one somatic variation, predicted pathogenic in silico by PolyPhen and SIFT, was observed in the mitochondrial genome---namely, *MT-ND5*:c.400G\>A, a component of complex I.

![Tumor cells are oncocytic and are heavily populated with mitochondria. Cell type in the primary and metastatic tumor tissue was assessed for oncocytic potential, by size, and appearance by H&E (*A*,*C*,*E*), as well as for the presence of mitochondria by SDHB staining (*B*,*D*,*F*).](MCS003764Mcc_F4){#MCS003764MCCF4}

Germline Genomic Analysis {#s2e}
-------------------------

We assessed the germline for any inherited, deleterious mutations in MMR or mitochondrial genes. No variants of interest were detected in MMR genes, except apparent polymorphisms recorded in dbSNP and 1000 Genomes, in *MSH3* (c.162-179del) and *PMS2* (c.706-4del). Similarly, a variant of unknown significance (conflicting in silico data but reported in dbSNP), in complex III gene *MT-CYB* (c.20C\>T), was detected. No germline mutations were detected in the commonly mutated *TP53*.

Liquid Biopsy {#s2f}
-------------

To enable early detection of cancer recurrence, we conducted a serial liquid biopsy of ctDNA, using ddPCR probes against the somatic *MSH2* c.1277-9_1292del deletion, and a reference control, targeting Chr 2:47600540. The *MSH2* deletion was detected only in the tumor tissue--derived DNA and not in any of the 10 subsequent liquid biopsies collected between June 2015 and November 2017 ([Fig. 5](#MCS003764MCCF5){ref-type="fig"}; [Supplemental Fig. S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)). The control targeted allele was present in all tissues and liquid biopsy time points. The *TP53*, *RB1*, and *MEN1* mutations were also analyzed in the germline, metastatic tumor DNA, and ctDNA and only detected in the metastases (data not shown). The data strongly support the clinical conclusion that the patient remains in remission, with no detectable signs of early disease progression.

![Liquid biopsy confirms patient is in remission. Liquid biopsy for ctDNA was acquired between June 2015 and November 2017. Droplet digital PCR probes were obtained to interrogate *MSH2*:c.1277-9_1292del (blue), in the germline, primary tumor, metastases, and across all ctDNA samples. We used a control probe to interrogate a wild-type Chr 2:47600540 (red). Presented here are the droplet digital PCR counts on a log~10~ scale.](MCS003764Mcc_F5){#MCS003764MCCF5}

DISCUSSION {#s3}
==========

We have conducted an extensive molecular characterization of tumor and serial liquid biopsies in an aggressive ACC case with two lung metastases. The primary and metastatic tumors were characterized by a mass hyperhaploidization event in the primary, and mutational signatures were associated with defects in MMR.

We hypothesize that this was driven by a driver-somatic, loss-of-function (LOF) deletion, detected in *MSH2*. In the primary ACC, it was found in association with a somatic missense mutation in *MLH1*. Digenic alterations in both proteins have been previously reported in hereditary nonpolyposis colorectal tumors ([@MCS003764MCCC69]); however, the *MLH1* mutation leads to a functional protein, albeit at reduced capacity compared to wild type ([@MCS003764MCCC54]). Both proteins are critical for normal MMR, although MSH2, as part of the MutS complex, is essential for single base pair repairs and DNA loop repairs encompassing indels. It is the latter function that can be associated with DNA slippage and consequently, MSI, as seen in the colorectal tumors above and others, including the metastatic ACC case presented herein ([@MCS003764MCCC15]). Furthermore, LOF *MSH2* deletions, induce a "mutator phenotype," which leads to (i) disrupted methylation of CpG islands, possibly accounting for the deamination of 5-methylcytosine signature, usually observed in aging individuals ([@MCS003764MCCC65]), and (ii) the elevated accumulation of mutations in oncogenes and tumor suppressor genes, including often in *TP53* ([@MCS003764MCCC71]).

p53 is a transcription factor considered the guardian of the genome, being implicated in regulating genes that control cell cycle and death, maintaining genome stability, and mediating cellular responses to genotoxic insults and hypoxia, among other functions ([@MCS003764MCCC48]). It is essential for arresting the cell cycle during G~1~, to allow for necessary DNA repair, prior to DNA replication ([@MCS003764MCCC48]). Our patient\'s somatic, mutational-hotspot *TP53* (p.Gly245Ser) variant, is known to disrupt DNA binding and, consequently, transcription ([@MCS003764MCCC40]). Dysfunctional p53 allows the cycle cell to continue unabated, even in the presence of erroneously mutated DNA ([@MCS003764MCCC48]; [@MCS003764MCCC40]). pRB is also essential for controlling the cell cycle and is the third most mutated protein in ACC ([@MCS003764MCCC56]). Our patient\'s LOF mutations in *RB1* and *TP53* may allow for the uncontrolled proliferation of cancerous lesions.

Intriguingly, p53 is also essential for mitochondrial genome stability, as well as mitochondrial respiration and energy production. Normal cells under aerobic conditions rely heavily on oxidative phosphorylation (OXPHOS), which for every molecule of pyruvate generates 36 molecules of adenosine triphosphate (ATP) ([@MCS003764MCCC73]). The alternative pathway is glycolysis, which produces just two ATPs under anaerobic conditions. Over the last 10 years, there has been renewed interest in energy metabolism in cancer, and emerging data is challenging the decades-old dogma that there is a preference to activate the glycolysis pathway while shutting down OXPHOS (for reviews, see [@MCS003764MCCC52]; [@MCS003764MCCC14]; [@MCS003764MCCC2]). Indeed, the majority of cancers do rely upon glycolysis to promote proliferation over differentiation ([@MCS003764MCCC26]; [@MCS003764MCCC72]), as compared to OXPHOS, it is quicker and generates more metabolites that are used as building blocks downstream for nucleic acids, proteins, and lipids ([@MCS003764MCCC73]; [@MCS003764MCCC72]). Further, glycolysis appears to be essential for cancer survival, as too much ATP generated by OXPHOS inhibits glycolysis and may result in more reactive oxygen species (ROS), which are dangerous to cancer cells ([@MCS003764MCCC73]; [@MCS003764MCCC2]; [@MCS003764MCCC12]). However, increasing data show that some cancers rely upon functioning OXPHOS and that this pathway is not entirely dependent upon glucose-derived pyruvate to function, and can, in fact, decouple itself from glycolysis. The citric acid cycle can feed off lactate, fatty acids, and amino acids such as glutamine to maintain OXPHOS in cancer ([@MCS003764MCCC52]; [@MCS003764MCCC14]). Metabolic processes in cancer, including that of the patient presented herein, require deeper investigation. However, based on our available data, we hypothesize that a metabolic switch has occurred from OXPHOS to glycolysis in our patient. The reasons are twofold. First, mitochondrial DNA is susceptible to OXPHOS-produced ROS, yet our patient exhibits only one somatic mutation. Second, our patient exhibits dysfunctional p53 and the somatic p.Arg233Ter mutation in *PTEN*. Both are known to induce a "hypoxia"-like microenvironment that favors glycolysis while suppressing OXPHOS ([@MCS003764MCCC45]; [@MCS003764MCCC73]; [@MCS003764MCCC34]; [@MCS003764MCCC2]). The evidence for the latter point in the literature is consequent activation of HIF1α, which induces transcription factors to facilitate adaptation to a hypoxic environment, as well as up-regulating nine of 10 glycolysis enzymes and blocking OXPHOS by inhibiting the conversion of pyruvate to acetyl CoA ([@MCS003764MCCC73]). Normally, p53 inhibits HIF1α expression, inhibits glycolysis, and increases SCO2 expression in the inner mitochondrial membrane, leading to increased OXPHOS ([@MCS003764MCCC73]; [@MCS003764MCCC2]). Our patient\'s mutations in *TP53* and *PTEN* have also been shown to induce activation of oncogene *AKT*, another factor which stimulates expression of HIF1α ([@MCS003764MCCC73]).

Active glycolysis may account for the qualitatively large presence of mitochondria that we observed in our swollen oncocytes, which may have occurred to compensate for the mass reduction in energy production due to the postulated suppression of OXPHOS, as described elsewhere ([@MCS003764MCCC16]). The cell cycle is an energy-intensive process, particularly for DNA replication and cell division. The lack of energy production may disturb mitotic spindle formation and function, resulting in unbalanced mitosis, with loss of chromosomes, as postulated by [@MCS003764MCCC16]. As multiple cell divisions occur, more chromosomes are lost, until the genome becomes near-haploid, which may be less energy-intensive to maintain than a diploid genome ([@MCS003764MCCC16]). Alternatively, mass haploidization/LOH may occur earlier than mitosis, with LOH having been observed to occur early in DNA replication ([@MCS003764MCCC53]). It has been hypothesized that entering a largely haploid state is a cancer-survival mechanism ([@MCS003764MCCC16]). It is noteworthy that in our patient, several chromosomes remained diploid, similar to those reported previously ([@MCS003764MCCC16]). This may provide a tumor survival advantage, such as for Chromosome 7, which contains oncogenes *cMET*, *EGFR*, and *BRAF* ([@MCS003764MCCC16]). Similar oncocytic phenotypes are observed in disparate cancer types; however, they are rare overall, which is consistent with the various mutations and metabolic preferences that occur across cancer.

With MSH2 as the postulated driver behind these complex series of events in our patient, we applied serial liquid biopsies between June 2015 (first metastatic resection) and November 2017 to monitor for relapse. Two other studies have applied liquid biopsy to ACC with very limited success. [@MCS003764MCCC17], detected somatic mutations in just one of the three patients with ACC, and observed decreases in mutation load following surgery in that patient. [@MCS003764MCCC28] similarly was able to track mutations in the ctDNA in just two of the eight patients with ACC. This may have been due to the larger tumor load, leading to higher levels of detectable ctDNA; however, tumor load was also high in cases where mutations were not detected ([@MCS003764MCCC28]). [@MCS003764MCCC28] postulated that this could be due to (i) slow progression of the tumor, (ii) low quantities of input ctDNA, or (iii) that ACC may be a poor secretor of ctDNA, such as seen in glioma or renal cell carcinoma ([@MCS003764MCCC9]). In the latter cancer type, a significant relationship was observed between ctDNA detectability and radiographic tumor burden in 34 patients, but not between ctDNA detectability and treatment response ([@MCS003764MCCC47]). Larger cohort studies are needed to confirm data for renal cell carcinoma, and we suggest the same is required for ACC before the utility of liquid biopsy in this cancer type is confirmed. Given the issues of ctDNA sensitivity outlined above, we chose ddPCR to sensitively monitor for the *MSH2* mutation, rather than NGS. ddPCR confirmed that the patient remained in remission. Our techniques were sound through the ability to detect the reference control allele in every germline, tumor, and ctDNA sample. It would have been preferable to obtain liquid biopsy at the time of primary ACC resection when the tumor burden would have been high. Unfortunately, blood was not preserved for the study herein at that time.

It is quite remarkable that our patient remains in remission. As stated previously, survival rates for ACCs are very low. Further, our patient had a high-grade Ki67 proliferation score of 60%--75% and a Weiss score of 5. In one study, 38% of patients with a Weiss score of \>3 had passed away within 5 yr ([@MCS003764MCCC46]). However, long-term survival is not unheard of in the literature, with cases of nonmetastatic disease, through to recurrent disease, surviving from 12 to 28 yr ([@MCS003764MCCC35]). Immunologically, our results suggest a tumor intrinsic induction of immune invasion as demonstrated by the constitutive activation of PD-L1 and lack of tumor-infiltrating lymphocytes. Such tumors have been defined as type III by [@MCS003764MCCC64]. Although speculative, the presence of high TMB, MSI, strong PD-L1 staining, but low T-cell numbers suggests there may be a rationale for this patient to receive a combination treatment in the event of relapse that would recruit T lymphocytes into the tumor microenvironment (e.g., anti-CTLA4 \[ipilimumab\]), but also inhibit PD-L1 if progression had occurred (e.g., anti-PD-1 \[pembrolizumab\]) ([@MCS003764MCCC50]; [@MCS003764MCCC19]).

Our data, however, uncover further interesting pathways that could be explored for targeted drug therapy particularly in the ACC setting, including mitochondrial metabolism and eventually p53. As targeted drug development and liquid biopsy continue to expand, with the shift from treating cancer based on its tissue of origin to its molecular profile (personalized medicine), therapeutic options against these targets are becoming, or may become, available ([@MCS003764MCCC55]). This is desperately needed for ACC, as mitotane is the only drug approved for its treatment, and response rates are very low.

In conclusion, we postulate that the somatic deletion in MMR gene *MSH2*, in a patient who presented with primary ACC and dual lung metastases, has induced a mutator phenotype and MSI. These events were associated with deactivation of p53 and PTEN, which has led to the change of mitochondrial energy production to favor glycolysis over OXPHOS. In turn, there has been an accumulation of mitochondria within the cancerous cells to compensate for the energy reduction, leading to mass haploidization/LOH. Follow-up experimentation is needed to confirm this hypothesis. Liquid biopsy has confirmed the clinical data that our patient remains in remission; however, combination immunotherapy appears to be the preferred treatment option in the event of relapse. Genomic stratification of rare/poorly studied malignancies is an effective means of identifying new therapeutic options, which, when applied with liquid biopsy, could help improve treatment plans and prognoses.

METHODS {#s4}
=======

Next-Generation Sequencing {#s4a}
--------------------------

Primary ACC tissue had previously been archived in formalin-fixed, paraffin-embedded (FFPE) blocks. Genomic DNA was extracted at Garvan Molecular Genetics, using QIAGEN\'s DNeasy kit (69504). Library preparation and targeted capture of 170 genes were conducted using the TruSight Tumor 170 Kit (Illumina OP-101-1003), with sequencing then performed using Illumina\'s NextSeq 500 System to 512× depth ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)) at the Kinghorn Centre for Clinical Genomics (KCCG).

For normal or metastatic tissues, DNA was extracted from fresh-frozen tissues using the AllPrep DNA/RNA/Protein Mini Kit (QIAGEN 8004) according to the manufacturer\'s instructions. Whole-genome sequencing (WGS) to intended coverage depths of 30× (normal tissue) and 90× (metastatic tumor tissue) ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)) was performed using Illumina\'s HiSeq X platform at KCCG.

Bioinformatics {#s4b}
--------------

### Targeted Sequencing of Primary Tumor {#s4b1}

Raw fastq files were uploaded to BaseSpace before being transferred to the cloud-based genomic analysis platform, DNAnexus ([www.dnanexus.com](www.dnanexus.com)). Paired-end short reads were aligned to the hs37d5 reference genome, using BWA-MEM (v0l7.10-r789) ([@MCS003764MCCC41]) and duplicates marked using Novosort (default settings), and then processed according to a series of quality scores ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003764/-/DC1)). Following the Genome Analysis Toolkit (GATK) best practices guidelines ([@MCS003764MCCC66]), read alignment and quality were improved using GATK IndelRealigner and GATK BaseRecalibrator (v3.3) ([@MCS003764MCCC66]). SNVs and insertions/deletions (indels) were called using VarDictJava (v1.4.6) ([@MCS003764MCCC39]), with copy number variants (CNVs) determined using CNVkit (v0.9.1), against a pooled reference panel of 60 FFPE germline controls ([@MCS003764MCCC63]). Tumor purity was assessed using PureCN (v1.10.0) with R (v3.6) ([@MCS003764MCCC59]) prior to annotation with Ensembl Variant Effect Predictor (VEP, v87).

### WGS of Germline and Metastatic Tumors {#s4b2}

Raw fastq files were processed through BWA-MEM and GATK as above. Germline SNVs and short (\<50-bp) indels were identified using GATK HaplotypeCaller (v3.3) in GVCF mode ([@MCS003764MCCC66]), with somatic variants identified using Strelka (v1.0.14) ([@MCS003764MCCC62]). Variants were then annotated with VEP, converted into a database using GEMINI ([@MCS003764MCCC51]), and imported into Seave ([@MCS003764MCCC29]) for filtration and prioritization. This was performed according to \<1% frequency in 1000 Genomes and Exome Aggregation Consortium (ExAC) databases, conservation (assessed by GERP), functional impact (PolyPhen-2 and SIFT), biological likelihood through candidate gene and pathway analysis, and association with known Catalogue of Somatic Mutations in Cancer (COSMIC) variants.

Tumor purity, CNVs, and structural variants were identified using PURPLE (<https://github.com/hartwigmedical/hmftools/tree/master/purity-ploidy-estimator>) (v1.1.0) and Manta (v0.27.1), respectively ([@MCS003764MCCC13]), and then annotated using Ensembl genes. SomaticSignatures (v.2.16.0) ([@MCS003764MCCC30]) was used to link observed SNVs to mutation generating processes, and assessment of MSI was conducted using Mantis (v1.0.3) ([@MCS003764MCCC37]).

Bcftools intersect (<https://samtools.github.io/bcftools/bcftools.html>) was used to compare the two metastases for conserved and novel variants.

T-Cell Receptor Sequencing {#s4c}
--------------------------

Normal- and tumor-derived DNA was analyzed for T-cell clonality for TCR-β rearrangements using the Lymphotrack TRB assay panel (Invivoscribe; cat. no. 72250019) according to manufacturer\'s instructions, with libraries sequenced by using Illumina\'s MiSeq v2 (500 cycle). A clonality estimate was calculated from the sum of the top 20 unique TCR-β rearrangements.

Fluorescence In Situ Hybridization {#s4d}
----------------------------------

Ploidy assessment was conducted according to manufacturer\'s instructions, using the ZytoLight SPEC BCR/ABL1 Dual Color Dual Fusion Probe, targeting t(9;22)(9q34.1;q11.2) (Zytovision Z-2111-200).

Immunohistochemistry {#s4e}
--------------------

All immunohistochemistry was conducted on 5-µm sections of tumor and normal tissue. Morphological analysis was assessed using H&E, before analysis of any tumor immunosuppression activity, using the 22C3 pharmDx Kit (Agilent) against programmed cell death ligand-1 (PD-L1), according to manufacturer\'s instructions. T-cell infiltration was assessed with anti-CD3 (Roche 790-43141) and CD8 (Agilent M7103) antibodies according to the manufacturer\'s instructions, as was qualitative assessment of mitochondrial staining using a mouse monoclonal antibody against SDHB (Abcam ab14714).

Liquid Biopsy {#s4f}
-------------

Blood samples were obtained from the patient quarterly between June 2015 and November 2017, into Streck BCT tubes (Streck), with immediate separation of plasma. ctDNA was immediately extracted from 4 mL plasma aliquots using the Circulating Nuclei Acid Kit (QIAGEN 55114) according to manufacturer\'s instructions, and frozen at −80°C. Somatic variants of interest were probed by droplet digital PCR (ddPCR), using the Bio-Rad QX200 Droplet Digital PCR System. Probes were obtained from Thermo Fisher Scientific.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Genomic data have been deposited at the European Genome-phenome Archive (EGA; <http://www.ebi.ac.uk/ega/>) under accession number EGA00001003497.
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